25 Posts Not to Miss from EHA 2025

The European Hematology Association (EHA) Congress 2025 is officially underway in Milan. From June 12 to 15, hematology professionals from around the world are gathering to share the latest research, clinical advances, and innovations shaping the future of hematologic care.

EHA 2025 features a comprehensive scientific program that includes high-level plenary sessions, oral abstract presentations, clinical and translational research highlights, and disease-specific updates across malignant and non-malignant hematologic conditions. With hundreds of abstracts presented, as well as interactive education sessions and collaborative forums, the congress offers unparalleled insight into evolving standards of care, novel therapies, and mechanisms of disease.

This year’s meeting also celebrates the 30th edition of the EHA Congress, a milestone reflecting three decades of scientific excellence, global collaboration, and commitment to improving outcomes for patients with blood disorders. The program places a strong emphasis on innovation, equity, and mentorship, highlighted by prestigious award recognitions honoring leaders in the field.

Our team at OncoDaily has handpicked 10 highlights from the firts day of EHA 2025. Scroll down to catch the highlights, dive into the science, and hear directly from the people shaping the future of cancer care.

ASH:

“New research finds women with BRCA1/2 mutations who received textured breast implants after mastectomy face a 16x higher risk of developing BIA-ALCL, a rare lymphoma. Study highlights need for awareness years after surgery.”

Nico Gagelmann:

Lymphoma Coalition :

” Lymphoma Coalition is pleased to see this important research on chronic lymphocytic leukemia (CLL) care featured at EHA2025. The poster and abstract focus on advancing shared decision-making in CLL, ensuring that care reflects the individual goals, preferences, and values of those living with the disease. CLL is the most common adult leukemia in the Western world, accounting for 1 in 3 cases. Treatments are improving, but there’s still work to do to make care truly person-centered — and shared decision-making is a vital part of that. We’re grateful to all the experts, advocates, and people living with CLL who made this collaboration possible. Let’s keep pushing for care that listens, adapts, and empowers. Read the abstract here: ”

Daniel Auclair:

“Nice summary of approved T-cell redirecting agents by Dr. Alvarez-Vallina.”

Talha Badar:

“Long-term follow-up of CALGB 10403 trial presented by Dr. Wendy Stock, 10 years OS 56%. T-cell ALL no relapses after 3 years. 3 patients had t-MN.

Late events in B-cell ALL after 3 years 25%.”

Daniel Auclair:

“Early Real-World analysis from CIBMTR of axi-cel at EHA 2025. 446 patients, including 232 (52%) who would not have been eligible for ZUMA-7. With a medium F/U of 12 months, ORR is 79%, CR 64%, CRS ≥3 is 5%, and ICANS 22%. Mostly in line with ZUMA-7.”

Callie Coombs:

“This was an amazing effort and practice-changing study for LGL leukemia – cyclophosphamide is superior to MTX with respect to ORR with comparable safety – took 10 years to accrue but shows that we can do RCT in rare hem diseases.”

Ajay Major:

Daniel Auclair:

“Impressive early data presented for JNJ’4496 dual CD19/CD20 CART in R/R LBCL at EHA2025. 100% ORR and 80% CR at RP2D. No Gr. 3/4 CRS to date, no prophylactic treatment for ICANS or CRS.”

C. Ola Landgren:

“Thank you EHA 2025 for inviting me to present our results from the randomized, multicenter randomized ADVANCE clinical trial for the treatment of patients with newly diagnosed multiple myeloma – at the annual meeting in Milan, Italy!

The study shows that the 4-drug combination with Daratumumab-Carfilzomib-Lenalidomide-dexamethasone (Dara-KRd) delivers significantly (p<0.0001; OR=2.9) higher MRD negativity rates compared to KRd. The results are consistent across subgroups. The progression-free survival analysis shows that at almost 3 years of follow-up, 92% of the patients treated with Dara-KRd) are are doing well and are free from progression. The study was open for enrollment, independent of transplant eligibility (transplant eligible, transplant ineligible, and transplant deferred). MRD negativity after 8 cycles of combination therapy was the primary endpoint. There were no new safety signals.

We conclude that Dara-KRd is a new standard of care for newly diagnosed multiple myeloma patients, independent of transplant eligibility.

Thank you to all patients and family who participated in the ADVANCE clinical trial for newly diagnosed multiple myeloma! Thank you to all our collaborators and thank you to our funding support!”

Talha Badar:

“EHA2025 all s/c blinatumomab for RR ALL, P1/1b data presented by Dr. Jabbour.
1. Given at 2 dose level, 250ug/500ug was better tolerated and selected for RP2D.
2. Responses were better compared to IV Blina.
3. Responses were seen among pts with prior IV blina exposed.”

Talha Badar :

“EHA 2025 – <3.3 mg/m2 vs >3.3 mg/m2 of Inotuzumab ozogamicin; impact on survival presented by Dr. Jabbour
1. Tolerance was better at lower dose with less myelosuppression.
2. Incidence of SOS was comparable.
3. Survival was better at lower dose, caveat more pts received allo-HCT among lower dose gp.”

NEJM:

“Presented at EHA2025:

Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years.

Full FLAIR phase 3 trial results: https://nej.md/3SMNdC4 ”

Talha Badar:

“Presentation by Dr. Bijal Shah.

1. Bridging therapy before CAR-T based on Ph status and disease burden.
2. Brexucel vs Obecel based on age, prior CAR-T/alloHCT and CD19 expression.”

Vincent Rajkumar:

“Just out: Mayo Clinic mSMART Risk Stratification of Myeloma EHA25

1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper

2/ Primary plasma cell leukemia is high risk myeloma

3/ We define Double-hit high risk myeloma ”

Daniel Auclair:

“Amazing presentation by Dr. Daniel Hodson on genomics of DLBCL to close EHA2025 . Beautiful innovative preclinical modeling. His message: we need to all speak the same language between biologists, translational scientists and clinical researchers for breakthroughs in DLBCL.”

Vivek Subbiah:

“Wow! Sunday morning brings an incredible trifecta – 2 NEJM papers + 1 The Lancet Haematology study dropping simultaneously with EHA2025! 1/3 Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia NEJM. ”

Anna Sureda:

“Power of Women in Hematology! Excellent EHA-EBMT Joint Session at EHA2025 in Milan.
Mari Subklewe, Alexandra Martínez-Roca, Konstanze Döhner. ”

Alexandra Martínez-Roca:

“It was a real pleasure to share this session with such brilliant and inspiring physicians. Very thankful for the support and the sense of community EHA 2025. ”

Amer Zeidan:

“Thank you European Hematology Association for a wonderful EHA2025 in beautiful Milano including an outstanding EHA president’s party overlooking el Duomo. Thoroughly enjoyed high quality presentations, collaborative meetings & planning practice-changing trials. Looking forward to EHA26. ”

Naveen Pemmaraju:

“Wonderful catch-up with Kordasti Lab & Sanam Loghavi”

Naveen Pemmaraju:

“Honored to present, on behalf of my co-authors, our Ph2 findings from CADENZA study PVEK ,CD123 for BPDCN at EHA25 .”

Jon Slmanton-Garcia:

“Back home after EHA2025.Probably the most infection-focused edition in years. Packed sessions,diverse topics And SO MUCH HEAT (Luckily EHA2026 = Stockholm).Excited to join young EHA. A society where everyone counts and multidisciplinarity means something.”

Sanam Loghavi:

“How milanese of EHA2025 , having the president’s reception on the rooftop of La Rinascente Hematology, shopping and breathtaking views of Duomo Milano … thank you
EHA well done.”

Sabrina Ranero Ferrari:

“Great talk by Guilherme Perini representing the land of no CAR T. This map says it all.”

To stay on top of everything happening at EHA 2025, keep following OncoDaily

Written by Nare Hovhannisyan, MD